We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

MMRC Names MDS Pharma Services as Preferred CRO

MMRC Names MDS Pharma Services as Preferred CRO

MMRC Names MDS Pharma Services as Preferred CRO

MMRC Names MDS Pharma Services as Preferred CRO

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MMRC Names MDS Pharma Services as Preferred CRO "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The Multiple Myeloma Research Consortium has announced that it has selected MDS Pharma Services to serve as its preferred Contract Research Organization.

In this role, MDS Pharma Services will manage and execute MMRC pre-clinical and clinical research efforts, including data management related to the tissue accrual into the MMRC Tissue Bank.

The MMRC will also recommend MDS Pharma Services to industry partners as additional protocols are brought through the Consortium.

"MDS Pharma Services offers a full spectrum of advanced scientific and technological expertise to significantly accelerate each step of the drug discovery and development pathways," said Nancy Sumberaz, President, the MMRC.

"We are proud to consider MDS Pharma Services a true partner in our efforts to bring new therapeutic options to patients as quickly as possible."

"MDS Pharma Services is honored to have been chosen by the MMRC and we are ready to bring our global capabilities and oncology expertise to bear on the effort to fight multiple myeloma," says Alan Morgan, Vice President and General Manager for Global Clinical Development, MDS Pharma Services.